UK approves prescription-only melatonin drug for childhood ADHD
Pharmaceutical Technology
OCTOBER 13, 2022
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Colonis Pharma’s melatonin oral solution for the treatment of sleep-onset insomnia in children and adolescents with attention-deficit hyperactivity disorder (ADHD). Colonis Pharma is a subsidiary company within Clinigen. Prescription-only vs OTC.
Let's personalize your content